Skip to main content
AmigoFish

Ep. 394 - Security concerns in U.S., China reshaping biotech

From BioCentury This Week · · 33 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Proposed U.S. Treasury rules (https://www.biocentury.com/article/661295) implementing the COINS Act would bar U.S. equity investments, joint ventures and co-development deals with China biotechs, potentially ensnaring Asia-to-West NewCos while leaving licensing intact. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the rule’s implications for cross-border dealmaking, the competitive opening it may create for European companies, and China’s narrower-than-feared draft export controls (https://www.biocentury.com/article/661279) on platform technologies. The analysts also discuss what drew Gilead to pay $1.3 billion (https://www.biocentury.com/article/661309) up front for stealth Shanghai biotech PepStar’s oral IL-23 peptide, and whether Merck and Moderna’s Phase III melanoma vaccine data (https://www.biocentury.com/article/661287) clear the bar for adoption.

View full story: https://www.biocentury.com/article/661319

#BiotechPolicy #ChinaBiotech #CrossBorderDeals #NewCos #CancerVaccines

00:00 Introduction 01:31 Treasury's COINS Act Proposal 05:15 NewCos Under COINS 13:20 China's Draft Export Controls 18:39 Pepstar's Gilead Deal 23:24 Merck-Moderna Melanoma Vaccine

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)

Back to BioCentury This Week · Report a problem